Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis
CONCLUSION: Oncologists may have increased flexibility regarding the frequency of administration of BTT along with their choice of agent. Our study showed no significant difference in the prevention of overall SRE or development of BTT-associated harms between the BTT regimens evaluated.PMID:37735019 | DOI:10.1016/j.clbc.2023.08.008
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Athira Jayan Akshara Singareeka Raghavendra Roland Bassett Carlos H Barcenas Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Orthopaedics | Reclast | Statistics | Study | Xgeva | Zometa